Company intelligence / Profile preview

ExeVir Bio

Ghent, Flemish Region, Belgiumexevir.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

ExeVir's lead compound XVR013m shows exceptional neutralization potency across both SARS-CoV-2 pre-Omicron and Omicron variants. The company has completed Phase 1a and Phase 1b studies for its first candidate drug with good pharmacodynamics and efficient GMP manufacturability. XVR013m is being developed to start a First in Human clinical trial in 2025.

Therapeutic areas: Infectious Diseases
Modalities: VHH antibodiesHeavy chain-only antibodiesMulti-specific antibodies
Industry: Biotech

Drug pipeline

7 assets

XVR013

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

VIB

Beyond the preview

Go deeper on ExeVir Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExeVir Bio.

Explore the full profile